Premium
Review article: the role of antisecretory therapy in the management of non‐variceal upper gastrointestinal bleeding
Author(s) -
TRIADAFILOPOULOS G.
Publication year - 2005
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2005.02717.x
Subject(s) - medicine , proton pump inhibitor , upper gastrointestinal bleeding , endoscopy , gastroenterology , incidence (geometry) , adverse effect , gastrointestinal bleeding , surgery , physics , optics
Summary Non‐variceal, upper gastrointestinal bleeding accounts for 300,000 hospitalizations annually in the US and the risk of rebleeding and mortality remain high. The aim of this study was to review the incidence and causes of non‐variceal upper gastrointestinal haemorrhage, criteria for early discharge, risk stratification and intravenous vs. oral proton‐pump inhibitor use. Peptic ulcer disease accounts for 45% of all admissions for upper gastrointestinal bleeding. Clinical and endoscopic predictors of adverse outcome have been identified. The Rockall scoring system identifies patients who can be considered for early discharge after endoscopy. Evidence supports the use of intravenous proton‐pump inhibitor therapy for patients with bleeding ulcers associated with high‐risk stigmata. Patients who are clinically stable and in whom upper endoscopy has shown an ulcer with a clean base or a flat pigmented spot have a low risk for rebleeding and may be discharged early on oral proton‐pump inhibitor therapy. Proton‐pump inhibitor treatment reduces ulcer rebleeding but does not affect overall mortality. In the US, most patients with ulcer bleeding have low‐risk stigmata, and thus, can be treated with oral proton‐pump inhibitors and discharged early.